ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "fibromyalgia"

  • Abstract Number: 1435 • ACR Convergence 2025

    Impact of Treatment With Upadacitinib on Non-Nociceptive Pain and Its Relevance for the Presence of Residual Symptoms in Axial Spondyloarthritis: Results from a Multicountry Observational Study

    Denis Poddubnyy1, Victoria Navarro-Compan2, Neil Basu3, Mohammad Naffaa4, Tianming Gao5, Christopher Saffore6, Jamie Urbanik7, Bhumik Parikh8, Peter Taylor9 and Philip J. Mease10, 1Division of Rheumatology, Department of Medicine, University Health Network and University of Toronto, Toronto, Ontario, Canada, and Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany; Department of Epidemiology, German Rheumatism Research Centre, Berlin, Germany, 2Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, 3Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, United Kingdom, 4The Azriel's Faculty of Medicine, Bar-Ilan University, Safed, Israel; The Rheumatology Unity, Galilee Medical Center, Naharyia, Israel, 5AbbVie, North Chicago, IL, 6AbbVie Inc., waukegan, IL, 7AbbVie, Grayslake, IL, 8AbbVie, Hillsborough Township, NJ, 9University of Oxford, Oxford, United Kingdom, 10Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA

    Background/Purpose: Upadacitinib (UPA), an oral JAK inhibitor, has demonstrated improvements in inflammation and nociceptive pain in late phase clinical trials of patients with axSpA.1,2,3 However,…
  • Abstract Number: 1014 • ACR Convergence 2025

    Factors Associated with Fibromyalgia Diagnosis amongst People Meeting Criteria: Results from UK Biobank

    Sung-A Kim, Gary Macfarlane and Marcus Beasley, University of Aberdeen, Aberdeen, United Kingdom

    Background/Purpose: The diagnosis of fibromyalgia (FM) is challenging due to its reliance on patient-reported symptoms, the absence of definitive biomarkers, and numerous overlapping comorbidities. Discrepancies…
  • Abstract Number: 1332 • ACR Convergence 2025

    Mid‐Infrared Spectroscopy for Enhanced Diagnosis of Rheumatic Diseases

    Gilad Halpert1, Yair Dankner2, Eri Govrin1, Abdulla Watad3, Omer Gendelman1, Shlomo Segev1, Yehuda Shoenfeld1 and Howard Amital1, 1Sheba Medical Center, Ramat Gan, Israel, 2Shenkar College of Engineering and Design, Ramar Gan, Israel, 3Tel Hashomer Medical Center, Ramat Gan, Israel

    Background/Purpose: Spectral analysis of liquid biopsies has recently emerged as a promising, non-invasive approach to improve the diagnosis of various pathologies. Our objective was to…
  • Abstract Number: 0814 • ACR Convergence 2025

    Pain Patterns in a Multicenter Randomized Trial of Early RA – Link Between Initially Sustained Joint Inflammation and Subsequent Non-inflammatory Pain Outcomes

    Annie Brink1, Johan Karlsson Wallman2, Jon T Einarsson1, Meliha Kapetanovic1, Elisabeth Mogard1, Elisabet Lindqvist1, Carmen Roseman1, Kristina Lend3, Merete Hetland4, Mikkel Ostergaard5, Kim Horslev-Petersen6, Dan Nordstrom7, Tuulikki Sokka-isler8, Bjorn Gudbjornsson9, Gerður María Gröndal9, Marte Heiberg10, Espen Haavardsholm10, Michael Nurmohamed11, Anna Rudin12, Ronald van Vollenhoven13, Till Uhlig10, Jon Lampa14 and Tor Olofsson2, 1Lund University, Skane University Hospital, Department of Clinical Sciences Lund, Rheumatology, Lund, Sweden, 2Lund University, Skane University Hospital, Department of Clinical Sciences Lund, Rheumatology, Lund, Skane Lan, Sweden, 3Department of Rheumatology and Amsterdam Rheumatology Center, Amsterdam University Medical Centers, Amsterdam; Department of Medicine, Rheumatology Unit, Center for Molecular Medicine (CMM), Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden, 4Copenhagen Center for Arthritis Research (COPECARE) and DANBIO, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup; Department of Clinical Medicine, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark, 5Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark, and Copenhagen Center for Arthritis Research, Center for Rheumatology, Rigshospitalet, Glostrup, Denmark, 6Danish Hospital for Rheumatic Diseases, University Hospital of Southern Denmark, Sønderborg; Department of Regional Health Research, University of Southern Denmark, Odense, Denmark, 7Division of Rheumatology, Helsinki University Hospital, Helsinki, Finland, 8Department of Medicine and University of Eastern Finland, Jyväskylä Central Hospital, Juväskylä, Finland, 9Landspitali University Hospital; Faculty of Medicine, University of Iceland, Reykjavik, Iceland, 10Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, 11Amsterdam Rheumatology and Immunology Center, Reade; Department of Rheumatology and Amsterdam Rheumatology Center, Amsterdam University Medical Centers, Amsterdam, Netherlands, 12Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy of University of Gothenburg, Gothenburg, Sweden, 13Department of Rheumatology, Amsterdam University Medical Centre, Amsterdam, Netherlands, 14Department of Medicine, Rheumatology Unit, Center for Molecular Medicine (CMM), Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden

    Background/Purpose: Emerging data indicate an uncoupling between pain and inflammation during the RA disease course, and comorbid fibromyalgia – thought to stem from central pain…
  • Abstract Number: 1254 • ACR Convergence 2025

    Symptom Burden and Treatment Experience in Fibromyalgia: Results From a National Patient Survey

    Lesley Arnold1, Zhao Yang2, Parul Houston2, Todd Grinnell2 and Daniel Clauw3, 1University of Cincinnati College of Medicine, Cincinnati, OH, 2Axsome Therapeutics, Inc, New York, NY, 3Chronic Pain and Fatigue Research Center, University of Michigan, Ann Arbor, MI

    Background/Purpose: Fibromyalgia (FM) is a chronic, widespread pain disorder driven by dysregulated central pain processing which substantially impairs daily function and quality of life. Approved…
  • Abstract Number: 0534 • ACR Convergence 2025

    Prevalence and Impact of Fibromyalgia on Disease Outcomes and Treatment in Axial Spondyloarthritis: 10-year Follow-up Data From the DESIR Cohort

    Clementina López Medina1, Sylvie Chevret2, Cedric Lukas3, Anna Molto4 and Maxime Dougados2, 1Department of Medicine, Hospital Universitario Reina Sofia, University of Cordoba, IMIBIC, Cordoba, Spain, 2Université Paris-Cité, Paris, France, 3CHU Montpellier, Montpellier, France, 4Assistance Publique Hôpitauxde Paris, Paris, France

    Background/Purpose: Concomitant fibromyalgia (FM) can be suspected in patients (pts) with axial SpA (axSpA) using the Fibromyalgia Rapid Screening Tool (FiRST).The objective of this study…
  • Abstract Number: 1245 • ACR Convergence 2025

    Efficacy And Safety of Low-dose Naltrexone In Fibromyalgia: An Updated Systematic Review And Meta-Analysis of Randomized Controlled Trials (RCTs)

    Rubab Rizwan, Sehneet Grewal, Sri Varsha Banda and Mohammad Hazique, Nuvance Health, poughkeepsie, NY

    Background/Purpose: Fibromyalgia is a chronic condition marked by widespread pain that can significantly reduce a patient’s quality of life. While low-dose naltrexone (LDN) has emerged…
  • Abstract Number: 0225 • ACR Convergence 2025

    Positive anxiety, depression and/or fibromyalgia screening on validated MDHAQ indices is seen in 30-50% of routine care patients with all rheumatic diagnoses

    Juan Schmukler1, Tengfei Li2 and Theodore Pincus1, 1Rush University Medical Center, Chicago, IL, 2Rush, chicago, IL

    Background/Purpose: Comorbid anxiety (ANX), depression (DEP), and fibromyalgia(FM) are reported as more common in patients with rheumatoid arthritis (RA) and other rheumatic diagnoses than in…
  • Abstract Number: 1244 • ACR Convergence 2025

    PACFiND: Co-Designing Principles To Inform Reconfiguration Of Fibromyalgia Care Across Health Systems

    Rosemary Hollick1, Marcus Beasley1, Ernest Choy2, Caroline Cupit3, Debra Dulake1, Teresa Finlay3, Louise Locock1, Paul McNamee1, Catherine Pope3, Elaine Wainwright1, David Williams4 and Gary Macfarlane1, 1University of Aberdeen, Aberdeen, United Kingdom, 2Division of Infection and Immunity, CREATE Centre, Cardiff University, Cardiff, United Kingdom, 3University of Oxford, Oxford, United Kingdom, 4University of Michigan, Michigan

    Background/Purpose: Fibromyalgia is a contested and poorly supported condition, characterised by widespread pain, fatigue, and cognitive symptoms, often compounded by stigma and delayed diagnosis. Existing…
  • Abstract Number: 0197 • ACR Convergence 2025

    Rheumatoid arthritis (RA) patients who screen positive for anxiety, depression, and/or fibromyalgia are more likely to report problems with sleeping, memory, and/or social activities than to have an abnormal rheumatoid factor or ACPA

    Theodore Pincus1, Juan Schmukler1 and Tengfei Li2, 1Rush University Medical Center, Chicago, IL, 2Rush, chicago, IL

    Background/Purpose: A symptom checklist and screening indices for anxiety (ANX), depression (DEP), and/or fibromyalgia (FM) on patient questionnaires such as a multidimensional health assessment questionnaire…
  • Abstract Number: 1242 • ACR Convergence 2025

    Relax the Body: Dual-Agent Nighttime Therapy for Fibromyalgia: Symptom Reduction Using Tricyclic Antidepressants and Muscle Relaxants

    Robert Katz1, Alexandra Katz Small2, Edwin Moore3 and Seth Adler4, 1Rush University Medical Center, Chicago, IL, 2Rheumatology Associates, CHICAGO, IL, 3University of Illinois Urbana Champaign, CHICAGO, IL, 4Rush University Medical Center, Chicago, IL

    Background/Purpose: Fibromyalgia (FM) is a multifaceted disorder defined by chronic widespread pain, sleep disruption, fatigue, and cognitive difficulties. Although the predominant theory behind FM pathogenesis…
  • Abstract Number: 1077 • ACR Convergence 2024

    Pragmatic Quantitative Rheumatologist 0–10 Visual Numeric Scale Estimates of Inflammation, Damage, and Patient Distress Have Face Validity and May Be as Informative as Formal 28 Joint Counts in Rheumatoid Arthritis

    Theodore Pincus1, tengfei Li2 and Juan Schmukler1, 1Rush University Medical Center, Chicago, IL, 2Rush University Medical Center, washington dc

    Background/Purpose: A 28 joint count of swelling (SJC), tenderness/pain on motion (TJC), and deformity/limited motion (DJC), is recommended to assess rheumatoid arthritis (RA) patient status.…
  • Abstract Number: 1323 • ACR Convergence 2024

    Drug Abuse Screening in Patients Who Fulfill the 2016 Fibromyalgia Criteria

    Laura Aline Martinez-Martinez1, Angelica Beltran-Barajas2, Mayra Nadia Quintanar-Cuevas3, David Vera Bustamante4, Itzel Palafox Sosa5, Karyme Zazil Velazquez-Zarza6, Salvador Zuñiga-Roman6 and Luz Angelica Viruel-Mejia7, 1Rheumatology Department - National Institute of Cardiology Ignacio Chavez, Mexico City, Distrito Federal, Mexico, 2Mental health outpatient clinic of the National Institute of Cardiology Ignacio Chavez, Mexico City, 3Mental health outpatient clinic of the National Institute of Cardiology Ignacio Chavez, México, Mexico, 4Benemerita Universidad Autonoma de Puebla, Heroica Puebla de Zaragoza, Puebla, Mexico, 5Escuela Superior de Medicina-Instituto Politecnico Nacional, Ciudad de México, Mexico, 6Mental health outpatient clinic of the National Institute of Cardiology Ignacio Chavez, Mexico City, Distrito Federal, Mexico, 7Rheumatology Departement at National Institute of Cardiology Ignacio Chavez - Universidad Autonoma del Estado de Hidalgo, Tula de Allende, Hidalgo, Mexico

    Background/Purpose: The clinical association of fibromyalgia with symptoms of anxiety and depression is well recognized [Uçar M, et al. J Int Med Res 2015;43(5):679-85]. Emotional…
  • Abstract Number: 1156 • ACR Convergence 2024

    Prevalence and Impact of Fibromyalgia in Patients with Idiopathic Inflammatory Myopathies

    Didem Saygin1, Juan Schmukler2, Kristin Wipfler3, Christopher G McKennan4, Jiaxuan Duan4, Kaleb Michaud5 and Yvonne Lee6, 1Rush University Medical Center, Chicago, IL, 2Rush University Medical Center, Division of Rheumatology, Chicago, IL, 3FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, 4University of Pittsburgh, Department of Statistics, Pittsburgh, PA, 5University of Nebraska Medical Center, Omaha, NE, 6Northwestern University, Chicago, IL

    Background/Purpose: Fibromyalgia (FM) is the prototypical central pain disorder that can be associated with rheumatic conditions such as rheumatoid arthritis, Sjogren’s disease and lupus. Patients…
  • Abstract Number: 1520 • ACR Convergence 2024

    The Influence of Trauma on Features of Type 2 SLE

    Jennifer Rogers1, Megan Clowse2, David Pisetsky3, Jayanth Doss4, Mithu Maheswaranathan5, Lisa Criscione-Schreiber5, Rebecca Sadun4, Kai Sun4 and Amanda Eudy6, 1Duke, Durham, NC, 2Duke University, Chapel Hill, NC, 3Duke University Medical Center, Durham, NC, 4Duke University, Durham, NC, 5Duke University School of Medicine, Durham, NC, 6Duke University, Raleigh, NC

    Background/Purpose: Type 2 SLE symptoms of fatigue, widespread pain, sleep and cognitive dysfunction occur commonly in SLE although their etiology is unknown.  Since trauma has…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 25
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology